AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27868359
Drug: Linagliptin add-on
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin add-on group (linagliptin 5 mg/day)
Trial: 27868359
Drug: Metformin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin group (1,500 mg/day)
Trial: 27868359
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (metformin 750 mg/day)
Trial: 21312345
Drug: Pain-avoidance treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-avoidance treatment (16 twice-weekly sessions of cognitive-behavioral therapy and exercise training)
Trial: 21312345
Drug: Pain-persistence treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-persistence treatment (16 twice-weekly sessions of cognitive-behavioral therapy and exercise training)
Trial: 21312345
Drug: Pain-avoidance treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-avoidance treatment
Trial: 21312345
Drug: Pain-persistence treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-persistence treatment
Trial: 11484963
Drug: Vinorelbine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine at 25 mg/m2 weekly for at least eight weeks
Trial: 7920274
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of one gram of Ambroxol in 500 ml of 0.9% saline daily for 5 days
Trial: 7920274
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received infusions of 500 ml 0.9% saline at the same intervals
Trial: 25413366
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (AngII) infusion
Trial: 19352186
Drug: Endoflex endotracheal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoflex endotracheal tube for oral intubation
Trial: 19352186
Drug: Conventional endotracheal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional endotracheal tube with stylet for oral intubation
Trial: 9405961
Drug: tianeptine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tianeptine (37.5 mg/day)
Trial: 9405961
Drug: imipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imipramine (150 mg/day)
Trial: 9405961
Drug: tianeptine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tianeptine (75 mg/day)
Trial: 24469436
Drug: Oesophageal cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oesophageal cooling with ice water (5 mL injected prior to RF energy delivery)
Trial: 22279570
Drug: Ang-2 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ang-2 levels in patients recently started on treatment
Trial: 19684105
Drug: Standard doxorubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
Trial: 19013285
Drug: Strawberry supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry supplementation (454 g/d, 112 kcal)
Trial: 19013285
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran bread (control, 65 g/d, 112 kcal, approximately 2 g beta-glucan)
Trial: 9862876
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy for chronic hepatitis C (24 weeks duration)
Trial: 9862876
Drug: Sustained viral
RxNorm normalized name: Sustain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained viral response to interferon therapy (n = 41)
Trial: 9862876
Drug: Sustained biochemical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained biochemical responses to interferon therapy
Trial: 8571994
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle exercises for 3 months (completed treatment)
Trial: 1677698
Drug: Infusion-related bacteraemias
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion-related bacteraemias
Trial: 21908754
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) treatment
Trial: 17966977
Drug: Pomegranate ellagitannin-enriched
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate ellagitannin-enriched polyphenol extract (POMx) - 710 mg or 1420 mg per day
Trial: 17966977
Drug: Pomegranate ellagitannin-enriched
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate ellagitannin-enriched polyphenol extract (POMx) - 1000 mg per day
Trial: 14981375
Drug: Metronidazole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (two 2-g doses, 48 hours apart)
Trial: 12411539
Drug: Lactate clamp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate clamp (LC) procedure with exogenous lactate infusion clamped at approximately 4 mM during exercise at 55% V(O2,peak)
Trial: 9820381
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. plus clarithromycin 500 mg b.i.d. (OAC)
Trial: 9820381
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus amoxicillin 1 g b.i.d. plus clarithromycin 500 mg b.i.d. (AC)
Trial: 7644398
Drug: Antituberculosis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antituberculosis treatment regimen including pyrazinamide, isoniazid, and rifampicin
Trial: 806396
Drug: 2% solution
RxNorm normalized name: Lidomar 2% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% solution of sodium cromoglycate
Trial: 30343388
Drug: rs11600655 CC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs11600655 CC, rs640908 CT, and rs66475048 GA genotypes
Trial: 18469662
Drug: 0.01% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% lidocaine solution (10 mL of 1% lidocaine in 1 L saline)
Trial: 11323346
Drug: Rapacuronium (RAP)
RxNorm normalized name: rapacuronium
DrugBank: Rapacuronium (DB04834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rapacuronium (RAP) 1.5 mg/kg
Trial: 11323346
Drug: Vecuronium (VEC)
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium (VEC) 0.1 mg/kg
Trial: 11323346
Drug: Vecuronium (VEC)
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after RAP
Trial: 11323346
Drug: Vecuronium (VEC)
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after VEC
Trial: 11323346
Drug: Vecuronium (VEC)
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after SUC
Trial: 9182212
Drug: Abciximab with
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab with low-dose heparin (initial bolus of 70 U per kilogram)
Trial: 9182212
Drug: Abciximab with
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab with standard-dose heparin (initial bolus of 100 U per kilogram)
Trial: 9182212
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with standard-dose heparin (initial bolus of 100 U per kilogram)
Trial: 7894540
Drug: Zolpidem (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (therapeutic doses)
Trial: 31603281
Drug: Soya lecithin
RxNorm normalized name: Soya Lecithin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya lecithin (1.5 g per day) in a custom-made biscuit
Trial: 25673440
Drug: Kuntai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai capsule (4 capsules tid, po for 12 weeks)
Trial: 25673440
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg qd, po for 12 weeks)
Trial: 25673440
Drug: Blank Control
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank Control (no drug addition)
Trial: 20888993
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment (chemotherapy started within 28 days of increased CA125 measurement)
Trial: 20888993
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (chemotherapy commenced at clinical or symptomatic relapse)
Trial: 18172907
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (75 mg)
Trial: 18172907
Drug: Venlafaxine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine IR (75 mg)
Trial: 10939428
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with PEM regimen: cisplatin 60 mg/m2, etoposide 40 mg/m2, mitomycin-C 7 mg/m2
Trial: 8755686
Drug: Fosinopril 20
RxNorm normalized name: fosinopril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 20 mg, once daily
Trial: 1584996
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of mifepristone (RU 486)
Trial: 3937189
Drug: Isoniazid and
RxNorm normalized name: Isoniazid and rifampin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid and Rifampicin without a third drug
Trial: 29704965
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy Skills Training Group (DBT‐ST)
Trial: 20728709
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL of 2% lidocaine with 1:50,000 epinephrine
Trial: 20728709
Drug: 3.6 mL
RxNorm normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mL of 2% lidocaine with 1:50,000 epinephrine
Trial: 18182617
Drug: Sequential docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential docetaxel (three cycles of doxorubicin at 75 mg/m2, followed by three cycles of docetaxel at 100 mg/m2, followed by three cycles of CMF)
Trial: 18182617
Drug: Concurrent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent docetaxel (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2, followed by three cycles of CMF)
Trial: 18182617
Drug: Control arms
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arms (sequential control: four cycles of doxorubicin at 75 mg/m2, followed by three cycles of CMF; concurrent control: four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by three cycles of CMF)
Trial: 18182617
Drug: Docetaxel treatment
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel treatment (both sequential and concurrent)
Trial: 2331957
Drug: Cisapride, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 10 mg four times a day
Trial: 2331957
Drug: Cimetidine, 400
RxNorm normalized name: Cimetidine, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 400 mg four times a day
Trial: 25016597
Drug: Low FODMAP
RxNorm normalized name: ProNourish Low FODMAP Enteral Suspension (French Vanilla)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low FODMAP diet (3.05 g/day)
Trial: 25016597
Drug: Typical Australian
RxNorm normalized name: Australian pine pollen extract
DrugBank: Casuarina equisetifolia pollen (DB10485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical Australian diet (23.7 g/day)
Trial: 17925871
Drug: SP+AS+PQ (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP+AS+PQ (0.75 mg/kg primaquine)
Trial: 10849921
Drug: Active feedback
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active feedback via practice visits from the pharmaceutical prescribing adviser
Trial: 8973990
Drug: Metformin HCL
RxNorm normalized name: metformin HCl
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin HCL 1,700 mg (single dose)
Trial: 8973990
Drug: Metformin HCL
RxNorm normalized name: metformin HCl
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin HCL 850 mg (multiple doses, 3 times daily for 19 doses)
Trial: 8973990
Drug: Metformin HCL
RxNorm normalized name: metformin HCl
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin HCL (single and multiple doses) in healthy subjects
Trial: 6085386
Drug: 5‐mg nitrendipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐mg nitrendipine tablet
Trial: 6085386
Drug: 10‐mg nitrendipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg nitrendipine tablet
Trial: 6085386
Drug: 20‐mg nitrendipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20‐mg nitrendipine tablet
Trial: 6085386
Drug: Liquid suspension
RxNorm normalized name: Inhalation Suspension
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid suspension of nitrendipine
Trial: 6085386
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses (5‐mg, 10‐mg, 20‐mg)
Trial: 30046610
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) at ST36-ST37, 20 minutes twice a day for five days
Trial: 30046610
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies including fluid resuscitation, anti‐infection, vasoactive agents, mechanical ventilation, supply of enteral nutrition, and glutamine
Trial: 27479098
Drug: Complicated Grief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complicated Grief Treatment (CGT) with a supportive person
Trial: 27479098
Drug: Complicated Grief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complicated Grief Treatment (CGT) without a supportive person
Trial: 25269885
Drug: Saxagliptin/metformin XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin/metformin XR 5/500 mg FDC tablet
Trial: 25269885
Drug: Saxagliptin/metformin XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin/metformin XR 5/1,000 mg FDC tablet
Trial: 25269885
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of saxagliptin and metformin XR
Trial: 20195158
Drug: Slow-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release melatonin (6 mg) given at bedtime for 4 weeks
Trial: 18343246
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 4 mg (titrated to 8 mg if needed)
Trial: 18343246
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg (titrated to 100 mg if needed)
Trial: 30409962
Drug: P53 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P53 inhibitor (1 μM bpV)
Trial: 20028464
Drug: No-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment group (waitlist)
Trial: 18556085
Drug: Modified Yale
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Yale insulin infusion protocol (MY group)
Trial: 15821487
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists (GnRH-A)
Trial: 10487267
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg orally twice daily
Trial: 10487267
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg orally three times daily
Trial: 9081556
Drug: Conditioned stimulus
RxNorm normalized name: Limulus polyphemus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioned stimulus plus 10 mg of cyclophosphamide
Trial: 1936485
Drug: Metformin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2 tabs/d, i.e. 1,700 mg/d)
Trial: 6217028
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive (30-40-30 micrograms EE and 50-75-125 micrograms levonorgestrel)
Trial: 6217028
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose oral contraceptive (30 micrograms EE and 150 micrograms desogestrel)
Trial: 6217028
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose oral contraceptive
Trial: 27052428
Drug: Albuvirtide (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuvirtide (320 mg) and Lopinavir/Ritonavir (400/100 mg)
Trial: 27052428
Drug: Lopinavir/Ritonavir (400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir (400/100 mg)
Trial: 23855176
Drug: Oral Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Midazolam 0.5 mg/kg
Trial: 23855176
Drug: Oral Diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Diazepam 0.5 mg/kg
Trial: 23855176
Drug: Intravenous Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Midazolam 0.06 mg/kg
Trial: 21394570
Drug: Pharmacotherapy follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy follow-up (PF)
Trial: 12520634
Drug: Capecitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,000 mg/m2 twice daily on days 1 to 14) plus IV irinotecan (250 mg/m2 on day 1 every 21 days)
Trial: 7521118
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate in combination with UFT (group B)
Trial: 4524016
Drug: Topical fluoride
RxNorm normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoride application once a year
Trial: 4524016
Drug: Topical fluoride
RxNorm normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoride application twice a year with 6 month interval
Trial: 4524016
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical fluoride application (control group)
Trial: 23594263
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human C1 inhibitor (rhC1INH) administered at a dosing scheme of 50 U kg(‐1) up to 84 kg, with a fixed dose of 4200 U above 84 kg.
Trial: 23594263
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human C1 inhibitor (rhC1INH) in symptomatic HAE patients.
Trial: 23594263
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human C1 inhibitor (rhC1INH) in healthy volunteers.
Trial: 21615875
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose CTPI (19.62 mSv)
Trial: 21615875
Drug: Median dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median dose CTPI (12.61 mSv)
Trial: 21615875
Drug: Low-dose CTPI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CTPI (7.01 mSv)
Trial: 21615875
Drug: Low-dose CTPI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CTPI in patients with HCC
Trial: 17109592
Drug: Twice-daily NPH/regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily NPH/regular insulin
Trial: 17109592
Drug: Once-daily glargine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily glargine insulin
Trial: 7520297
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution with low molecular weight hydroxyethyl starch (HS-HES)
Trial: 7520297
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight hydroxyethyl starch solution (LMW-HES)
Trial: 2837106
Drug: terbutaline (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline (7 micrograms/kg, subcutaneous injection)
Trial: 22585541
Drug: loose snus
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loose snus (27.1 mg nicotine)